NCT03492099View on ClinicalTrials.gov

Assessing the Safety of Buprenorphine in People With Sickle Cell Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

August 1, 2018

Primary Completion Date

September 23, 2019

Study Completion Date

February 28, 2022

Conditions
Sickle Cell Disease
Interventions
DRUG

buprenorphine

Patients in this study will receive dosages to be determined by a physician that are specific to each patient.

Trial Locations (1)

21205

Johns Hopkins Hospital, Baltimore

All Listed Sponsors
lead

Johns Hopkins University

OTHER

NCT03492099 - Assessing the Safety of Buprenorphine in People With Sickle Cell Disease | Biotech Hunter | Biotech Hunter